Analyst Price Target is $2.85
▲ +378.99% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Precipio in the last 3 months. The average price target is $2.85, with a high forecast of $2.85 and a low forecast of $2.85. The average price target represents a 378.99% upside from the last price of $0.60.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Precipio. This rating has held steady since March 2022, when it changed from a Buy consensus rating.
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Read More